Wedbush Starts Sutro Biopharma (STRO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Cowen Starts Sutro Biopharma (STRO) at Outperform
October 22, 2018 5:40 AM EDTCowen analyst Boris Peaker initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Outperform rating.
The analyst comments "Sutro is an early-clinical stage biopharma company that uses its XpressCF platform to generate optimized biologics. This platform generates a homologous pool of ADC... More
JMP Securities Starts Sutro Biopharma (STRO) at Market Outperform
October 22, 2018 4:04 AM EDTJMP Securities analyst Konstantinos Aprilakis initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Market Outperform rating and a price target of $28.00.
The analyst comments "Sutro is a clinical-stage biopharmaceutical company evolving novel methods to discover and develop protein-based therapies, with the... More
Piper Jaffray Starts Sutro Biopharma (STRO) at Overweight
October 22, 2018 3:45 AM EDTPiper Jaffray analyst Edward Tenthoff initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Overweight rating and a price target of $23.00.
The analyst likes the revolutionary XpressCF platform, the potential upside from STRO-001 Phase 1 data in 2019, benefits from STRO-002 advancing into Clinic and... More
